Tulane University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tulane University sits in the top decile of US sponsors by registered trial count (#295 of 15,742 sponsors by registered trial count).
Tulane University: 73 sponsored US clinical trials, 22 recruiting.
Tulane University sponsors 73 registered US clinical trials on ClinicalTrials.gov, 22 of them currently recruiting, and 36 completed. 6 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 6 trials.
Top-decile sponsor footprint
Tulane University ranks in the top decile of sponsors by registered trial count (#295 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
36 of 40 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
73 total, page 1 of 2
Continuous Glucose Monitoring (CGM) in an Underserved Population
NCT07135531
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
NCT07077902
Ultra-Low Contrast Angiography in AKI
NCT05906758
A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities
NCT06428643
The Cooking for Health Optimization and Disease Prevention (CHOP) Trial
NCT07011459
Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
NCT06261840
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
NCT06835686
Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology
NCT06753045
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
NCT06116149
M-O-M-S on the Bayou: Implementation of an Intervention for Mental Health in Pregnancy
NCT05838404
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
NCT06133322
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
NCT06065098
Sodium Lowering Vascular Effects Trial
NCT05388032
Supportive Hospital-Based Intervention for Firearm Trauma
NCT06712940
Medication Adherence Program
NCT05183763
Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
NCT05014802
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
NCT05159466
The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study
NCT04947657
PPG to Predict Ejection Fraction and Other Echographic Data in the General Population
NCT04843371
Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study
NCT04814420
The Allergen Reduction and Child Health Study (ARCHS)
NCT04331353
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
NCT04956445
The Effect of Reading Therapy on Newborns
NCT05004857
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
NCT04733469
Transplacental Transmission of RSV (TTRSV)
NCT05443607
Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control in Minimize Cognitive Decline
NCT04797403
Bogalusa Heart Study
NCT00005129
The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
NCT04007276
Implementation Models for Blood Pressure Monitoring in Pregnancy and Postpartum: Connected MOM Plus
NCT07691541
Enhancing Diabetes Care by Treating Insomnia
NCT07062406
The RESPLASH Study
NCT06880562
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
NCT04601233
The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients
NCT05279937
Building Engagement Using Financial Incentives Trial - Hypertension
NCT06195839
LA-CEAL 4.0: Wearable Sensor Project
NCT06086028
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening
NCT06124131
Lupus Education Alliance Program
NCT05243875
NOLA GEM: Feasibility and Acceptability of an MHealth Intervention for Violence-affected PLWH
NCT05784714
Potassium Intake-response Trial to Control Hypertension
NCT05758142
Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
NCT05281718
Maternal Health Diabetes Prevention Study
NCT05343494
Text My Hypertension BP Meds NOLA
NCT05074173
Intervention to Improve Caregiver Palliative Care Knowledge and Attitudes
NCT05162807
Virtual Mom Power With High-Adversity Mothers and Children (MPHAMC)
NCT05129397
Epigenetic Analysis of Regulation of the Inflammasome-activating NLRP3 Gene in Monocytes From Atrial Fibrillation Patients and Controls
NCT04766814
Real World Study of COVID-19 in a Flyover Region
NCT04962347
Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate
NCT04930965
Estradiol and Progesterone in Hospitalized COVID-19 Patients
NCT04865029
Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study
NCT04769310
Personality and Cancer Care Study
NCT04625439
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the Tulane University pipeline
22 recruiting of 73 indexed (30% open); 36 completed (49%).
Phase mix: 6 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Hypertension (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tulane University: open-pipeline peers nationwide
Peers matched on 73 registered trials and 30% open enrollment, not the therapeutic-area sidebar.
Tulane University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 73 trials (± recruiting share)
- Denver Health and Hospital Authority · 73 trials · 5% recruiting
- Hugo W. Moser Research Institute at Kennedy Krieger · 73 trials · 23% recruiting
- Joslin Diabetes Center · 73 trials · 10% recruiting
- Massachusetts Eye and Ear Infirmary · 73 trials · 27% recruiting
Sponsors near 30% open enrollment (± trial volume)
- New York University · 30% recruiting · 83 trials
- University of New Mexi · 30% recruiting · 76 trials
- Adverum Biotechnologies · 30% recruiting · 10 trials
- Centre hospitalier de l'Université de Montréal (CHUM) · 30% recruiting · 10 trials
Related
What to do with this Tulane University page
73 registered trials is a research-attention snapshot, not an endorsement of Tulane University or any single study.
- 22 of Tulane University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hypertension is the condition Tulane University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tulane University pipeline card: 73 registered trials from official public datasets.Report a data error.